The LYAR Knockout Raji Polyclonal Cells product comprises a genetically edited population of Raji B-lymphoblastoid cells, generated via CRISPR/Cas9-mediated disruption of the LYAR gene locus to establish a polyclonal loss-of-function model. This engineered cell population is designed to abolish LYAR protein expression across a heterogeneous allele-editing spectrum, enabling robust interrogation of nucleolar oncoprotein biology in a highly reproducible cellular background. The polyclonal format provides researchers a flexible platform for pooled functional genomics, drug response profiling, and pathway analysis without clonal selection artifacts, while retaining the critical B-cell context relevant to hematologic malignancies and Epstein-Barr virus (EBV)-driven transformation.
Raji is an EBV-positive Burkitt lymphoma-derived B lymphoblastoid cell line that constitutively expresses viral latent genes, including EBNA and LMP proteins, which drive proliferation and survival signaling. This cell line models key features of high-grade B-cell lymphomas, including Myc deregulation and PI3K/AKT pathway activation, and is widely used to dissect mechanisms of lymphomagenesis, viral oncogenesis, and immune evasion. The engineered knockout of LYAR in this background permits direct assessment of how a nucleolar regulator interfaces with oncogenic signaling networks critical for malignant B-cell growth and therapeutic resistance.
LYAR encodes a nucleolar zinc-finger protein that functions as a transcriptional regulator and critical facilitator of ribosome biogenesis. Mechanistically, LYAR is directly activated by c-Myc and the PI3K/AKT signaling axis, and it interacts with chromatin remodeling factors and arginine methyltransferases PRMT1 and PRMT5 to modulate rRNA gene expression. LYAR promotes the processing and maturation of ribosomal RNA, coupling growth factor signals to ribosome production and protein synthesis capacity. Disruption of LYAR induces nucleolar stress, leading to ribosomal protein L5- and L11-mediated inhibition of MDM2, subsequent stabilization of p53, and activation of canonical p53 target genes that execute cell cycle arrest and apoptosis. This positions LYAR at a nexus where mTOR-driven anabolic signals converge with nucleolar surveillance and tumor suppressor networks.
In the Raji lymphoma context, LYAR knockout generates a unique model to study how nucleolar stress interfaces with EBV-driven oncogenesis. The co-existence of viral latency programs with altered ribosome biogenesis and p53 pathway engagement provides a physiologically relevant system to probe the crosstalk between viral oncoproteins, mTOR signaling, and nucleolar integrity. The polyclonal knockout population amplifies the model??s utility for studying clonal adaptation to ribosome biogenesis defects, identifying synthetic lethal interactions, and screening for compounds that modulate nucleolar stress-induced apoptosis in aggressive B-cell malignancies.
Typical experimental workflows include Western blotting for p53 stabilization and ribosomal protein localization, RT-qPCR for rRNA processing intermediates and transcriptional targets, and immunofluorescence to visualize nucleolar disruption and nucleophosmin redistribution. The cells are suited for flow-cytometric analyses of cell cycle arrest and apoptosis, as well as RNA-seq and co-immunoprecipitation to map LYAR interactomes and downstream transcriptional changes. These applications underpin therapeutic target validation studies for acute myeloid leukemia, Burkitt lymphoma, breast cancer, and glioblastoma, and support preclinical research into ribosome biogenesis inhibitors and nucleolar stress inducers. For further technical information or custom gene-editing requests, please contact Ascent Research.
